We examined potential liver‐related adverse effects, specifically lobular inflammation and hepatic steatosis in WT, Epm2a−/− and Epm2b−/− mice, 5 months after IV injection of the rAAVP31‐Null, rAAVP31‐hEPM2A, or rAAVP31‐hEPM2B vectors, using H&E staining. Here, EPM2A is linked to steatosis.